An interventional study of Supervised Resistance Exercise and Aerobic Exercise (Brisk Walking) in Sarcopenia and Rheumatoid Arthritis (RA), sponsored by Ankara Etlik City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Ankara Etlik City Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Sarcopenia with a site in Turkey — 36 open to participants now, 43 under way, none of them phase 3. Sarcopenia · Turkey.
Among the 131 studies in Sarcopenia with a site in Turkey, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 21 that started in 2024, is one of 32 with no phase, and was the 131st registered.
1,333 studies on the registry are indexed under Sarcopenia; 419 are open to participants now.
Browse Sarcopenia studies →36 of the 131 studies in Sarcopenia with a site in Turkey are open now. Recruiting first, the newest first:
Marmara University · Sites in Turkey
Ages 50–75
Izmir Democracy University · Sites in Turkey
Ages 6–18 · Healthy volunteers
Tarsus University · Sites in Turkey
Ages 65–80
Van Training and Research Hospital · Sites in Turkey
Ages 60+
Istanbul Saglik Bilimleri University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 247 Sarcopenia studies recruiting now, 154 (62%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 21 started in 2024.
This study's enrollment of 48 is below the median of 60 across 857 interventional studies indexed under Sarcopenia.
Median enrollment 40 across the 34 interventional studies, 100 across the 97 observational. Of the 76 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 131 have an industry lead sponsor. The 10 most frequent:
Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 78 are open to participants now.
Ankara Etlik City Hospital has 9 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
18 of the studies in Sarcopenia with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07813702MERT UYSALURINARY INCONTINENCE AND GERIATRIC SYNDROMES | 2026-11 |
| NCT07858864Istanbul Saglik Bilimleri UniversityGLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | 2026-11-30 |
| NCT07842731Atılım UniversityInvestigation of the Prevalence of Sarcopenia and Dynapenia According to Disease Stage in Patients With Multiple Sclerosis and Evaluation of the Relationship Between Sarcopenia Severity and Clinical and Functional Parameters | 2026-12-10 |
| NCT06749340Bahçeşehir UniversityExamining the Effects of Different Resistive Exercise Programs in Individuals With Compensated Liver Cirrhosis | 2026-12-23 |
| NCT07357662Tarsus UniversityEffects of Rehabilitative Exergame Training on Foot Muscle Activity, Balance, and Mobility in Older Adults | 2026-12-30 |
Add all 18 to your calendar (.ics) → With an account.
Among the 131 studies in Sarcopenia with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia is a common complication of rheumatoid arthritis (RA), and resistance exercise is the main recommended treatment. This study evaluated the prevalence of sarcopenia and its associated factors in RA patients aged 18 to 65 years, and tested whether adding aerobic exercise to resistance exercise provides additional benefit. RA patients were screened for sarcopenia according to EWGSOP2 criteria (handgrip strength, bioelectrical impedance analysis, and 4-meter gait speed). Regional sarcopenia was assessed with ultrasonography using the sonographic thigh adjustment ratio (STAR). Patients with sarcopenia who were eligible for exercise were randomized into two groups for 12 weeks: resistance exercise alone, or resistance exercise plus brisk walking. Muscle strength, muscle mass, physical performance, ultrasonographic muscle thickness, disease activity, function, and quality of life were compared before and after the program.
This was a single-center study conducted at the Rheumatologic Diseases Outpatient Clinic of the University of Health Sciences Ankara Etlik City Hospital, Physical Medicine and Rehabilitation Hospital, between January 2024 and April 2025. It had two phases.
Phase 1 was cross-sectional. RA patients aged 18 to 65 years, diagnosed by the 2010 ACR/EULAR criteria, were evaluated for sarcopenia by EWGSOP2 criteria. Handgrip strength was measured with a digital hand dynamometer, muscle mass with bioelectrical impedance analysis, and physical performance with 4-meter gait speed. Anterior thigh and anterior arm muscle thickness were measured by ultrasonography, and STAR was calculated as thigh muscle thickness divided by body mass index.
Phase 2 was a randomized, parallel-group exercise trial. Patients diagnosed with sarcopenia who met the exercise eligibility criteria were randomized by the sealed-envelope method into two groups. Both groups attended supervised group exercise sessions of 60 minutes, twice a week, for 12 weeks. Each session included warm-up, range-of-motion exercises, balance training, progressive resistance exercise, and cool-down. The second group was additionally asked to do 30 minutes of brisk walking at home on two other days each week.
Assessments were repeated at week 12. Outcomes included handgrip strength, skeletal muscle mass, gait speed, ultrasonographic muscle thickness, ESR, CRP, SDAI, pain VAS, HAQ, and RAQoL.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria Age 18 to 65 years Sarcopenia diagnosed according to EWGSOP2 criteria Low or remission disease activity (SDAI 11 or below) Normal cognitive function, able to speak and understand Turkish Willing to participate and provide written
Exclusion Criteria:
below 20 or above 40 kg/m² Another inflammatory disease besides rheumatoid arthritis Pregnancy Immobilization for more than 15 days in the last 6 months use in the last 3 months Uncontrolled diabetes mellitus Congestive heart failure Cardiac pacemaker Advanced liver or kidney failure Orthopedic surgery such as amputation or total knee or hip replacement Neurological disease such as cerebellar disease or multiple sclerosis Hand deformity or arthralgia preventing grip strength measurement Lower limb deformity preventing walking Advanced arterial or venous insufficiency, thrombosis, or thrombophlebitis Low trunk or lower limb muscle strength (Medical Research Council grade 3 or below) Poor balance (Berg Balance Scale score below 21)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with sarcopenia received the supervised resistance exercise program only.
Behavioral: Supervised Resistance Exercise
Patients with sarcopenia received the same supervised resistance exercise program plus brisk walking.
Behavioral: Supervised Resistance Exercise · Behavioral: Aerobic Exercise (Brisk Walking)
12 weeks of supervised group exercise, 60 minutes per session, twice a week. Each session includes 5 minutes of warm-up, 10 minutes of range-of-motion exercises, 20 minutes of balance training, 20 minutes of progressive resistance exercise with ankle weights and elastic bands at 60-70% of one-repetition maximum (Borg 11-13), and 5 minutes of cool-down.
30 minutes of brisk walking at home on two additional days each week for 12 weeks, with 5 minutes of warm-up and 5 minutes of cool-down, at a Borg score of 11-13. Adherence was checked weekly.
Change in handgrip strength
Dominant and non-dominant handgrip strength measured with a digital hand dynamometer (kg)
Time frame: Baseline and week 12
Change in skeletal muscle mass index (SSMI)
Skeletal muscle mass measured by bioelectrical impedance analysis and divided by height squared (kg/m²)
Time frame: Baseline and week 12
Change in physical performance
Usual gait speed over 4 meters (m/s)
Time frame: Baseline and week 12
Change in ultrasonographic anterior thigh muscle thickness
Thickness of rectus femoris plus vastus intermedius measured by ultrasonography on dominant and non-dominant sides (mm)
Time frame: Baseline and week 12
Change in ultrasonographic anterior arm muscle thickness
Thickness of biceps brachii plus brachialis measured by ultrasonography on dominant and non-dominant sides (mm)
Time frame: Baseline and week 12
Change in sonographic thigh adjustment ratio (STAR)
Anterior thigh muscle thickness (mm) divided by body mass index (kg/m²)
Time frame: Baseline and week 12
Change in sarcopenia status
Sarcopenia classification according to EWGSOP2 criteria
Time frame: Baseline and week 12
Change in disease activity
Simplified Disease Activity Index (SDAI)
Time frame: Baseline and week 12
Change in pain
Pain on a 0-10 cm visual analog
Time frame: Baseline and week 12
Change in functional status
Health Assessment Questionnaire (HAQ), score 0-3, higher is worse
Time frame: Baseline and week 12
Change in quality of life
Rheumatoid Arthritis Quality of Life questionnaire (RAQoL), score 0-30, higher is worse
Time frame: Baseline and week 12
Change in inflammatory markers
Erythrocyte sedimentation rate (mm/h) and C-reactive protein (mg/L)
Time frame: Baseline and week 12
Ran from Jan 2024 to primary completion in Apr 2025, 15 months.
Of 495 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's 15 months is below that.
Counting every sponsor, half of 506 studies reached it within 18 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.